• In >95% of patients, high triglycerides reflect the burden of the effects of more than 30 genes involved in triglyceride pathways
• Published in Lancet Diabetes & Endocrinology,¹ Free to download from 31 January – 28 February 2014 at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70191-8/fulltext

From University of Rochester Medica Center: University of Rochester Medical Center cardiologists are first in Upstate New York to offer a blood-cleansing therapy for people with extremely high cholesterol, including two-time heart attack survivor Bob Guesno, whose cholesterol level was nearly three times the norm.  

Heart & Vascular Center doctors have introduced apheresis to filter excess cholesterol from the body, providing a potentially life-saving reduction in the risk of stroke or heart attack for people with hypercholesterolemia.

The NLA was recently awarded Best Practice in Educational Design & Evaluation by the National Association of Medical Education Companies (NAMEC). The award recognizes the work of the NLA, along with its educational partner, MCM Education, for a series of activities in 2012-2013 titled Managing Residual CVD Risk: The Role of HDL Cholesterol.

The National Lipid Association (NLA) is excited to announce it has submitted a proposal to the National Center for Health Statistics (NCHS) to create new, specific ICD-10 codes for FH, which would include homozygous FH and heterozygous FH. The NCHS is the Federal agency responsible for revising the ICD codes and will review this proposal. The NLA worked collaboratively with The FH Foundation to draft this proposal that will have a profound impact on the diagnosis and treatment of FH.

Joyce Ross is a Nurse Practitioner with a long history of treating FH patients, but she also has a personal experience with the inherited disorder. When Joyce’s husband Jerry was 43 years old, he was diagnosed with FH.

I have worked in lipid clinics for over 25 years as a Clinical Dietitian Nutritionist and the past 4 years as a Clinical Lipid Specialist.   In 2007, I started exploring continuing education in lipid management.  I attended a meeting of a preventive cardiology association and heard about the NLA and joined later that year.  I have never been a part of

We are sad to report that we learned last week that Dr. Roger Illingworth passed away in early November after a long illness. He was a founding member of the NLA Board. Dr. Illingworth’s  career was dedicated to understanding, preventing and treating patients with cholesterol and lipid disorders and heart disease, and his research was instrumental in the development of the statin drugs from the earliest days. Our thoughts and prayers go out to Dr. Illingworth’s family.

2014 NLA Honors & Awards

To honor the exceptional professionals in our ranks, the NLA has established several types of recognition. We are currently seeking nominations for the following awards, to be presented at the 2014 Annual Scientific Sessions in Orlando, Florida (May 1-4, 2014):

Fellow of the NLA